Syngene International growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+2.6%+5.4%
EBITDA−11.8%−0.6%
Net Income−36.2%−12.0%
EPS (adj.)−36.2%−12.0%
Total Assets+3.8%+6.6%
Total Equity+2.4%+10.2%
Free Cash Flow+37.6%+21.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹16,060 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+2.6+5.4
EBITDA-11.8-0.6
Net Income-36.2-12.0
EPS (adj.)-36.2-12.0
Total Assets+3.8+6.6
Total Equity+2.4+10.2
Free Cash Flow+37.6+21.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.